Raptor Pharmaceutical (RPTP) : The total money flow in Raptor Pharmaceutical (RPTP) was negative ($7.96 million), which signals selling by the traders on Tuesdays session. They trimmed their holdings by selling the stock on downticks to the tune of $9.68 million. In comparison, the inflow of money into the stock on upticks was $1.72 million. The uptick to downtick ratio was 0.18. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $8.4 million. The value of transactions on uptick was $0.29 million. The negative money flow of ($8.11 million) confirms the selling in Raptor Pharmaceutical (RPTP) on strength. The uptick to downtick ratio of block trades was 0.03. Raptor Pharmaceutical (RPTP) gained $0.13 at $7.67, a gain of 1.72% over the previous days close. However, the stock registered 5.5% in the week.
Also, Citigroup maintains its rating on Raptor Pharmaceutical (NASDAQ:RPTP). The global brokerage major raises the current price target from $6 per share to $8 per share. Analysts at the Citigroup have a current rating of Neutral on the shares. The rating by the firm was issued on August 9, 2016.
Shares of Raptor Pharmaceuticals Corp. rose by 5.07% in the last five trading days and 26.36% for the last 4 weeks. Raptor Pharmaceuticals Corp. is up 34.8% in the last 3-month period. Year-to-Date the stock performance stands at 47.5%.
Raptor Pharmaceutical (NASDAQ:RPTP): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.52 and $7.42 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.77. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.67, notching a gain of 1.72% for the day. The total traded volume was 2,480,229 . The stock had closed at $7.54 on the previous day.
In a related news,The director of Raptor Pharmaceutical Corp, Bruhn Suzanne Louise sold 18,258 shares at $12.47 on September 9, 2015. The Insider selling transaction had a total value worth of $227,677. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Companys product, PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine, received a marketing authorization from the European Commission (EC), as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Companys pipeline includes its delayed-release form of cysteamine, or RP103 and its oral 4-methylpyrazole, or Convivia. Its other product, Quinsair, is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.